Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL D WILLIAMS

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1750334470
CMS profile
170642
Location
COLUMBIA, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$40,123.85

189 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 189 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL D WILLIAMS

NPI 1750334470 · CMS profile ID 170642

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

COLUMBIA, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 189 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750334470?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL D WILLIAMS, NPI 1750334470, CMS profile ID 170642. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 189 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750334470?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MICHAEL D WILLIAMS, NPI 1750334470, CMS profile ID 170642. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 189 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750334470?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MICHAEL D WILLIAMS, NPI 1750334470, CMS profile ID 170642, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 189 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1750334470?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

189 matching records · $40,123.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 189 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 189.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $18.5409/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137698042 CMS
ABBVIE INC. $17.7909/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106342083 CMS
Takeda Pharmaceuticals U.S.A., Inc. $11.3108/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137698040 CMS
Phathom Pharmaceuticals, Inc. $38.3308/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151139583 CMS
Phathom Pharmaceuticals, Inc. $83.7508/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151139585 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.6508/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153720381 CMS
AIMMUNE THERAPEUTICS, INC. $15.1208/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147013006 CMS
IRONWOOD PHARMACEUTICALS, INC $19.8008/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153724192 CMS
Lilly USA, LLC $34.3108/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135232344 CMS
Takeda Pharmaceuticals U.S.A., Inc. $10.0008/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137698038 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.8908/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137698036 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.6308/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137698034 CMS
Janssen Biotech, Inc. $12.5508/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078782580 CMS
Regeneron Healthcare Solutions, Inc. $20.8608/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114255673 CMS
PFIZER INC. $16.9308/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131854783 CMS
Phathom Pharmaceuticals, Inc. $2,150.0008/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151139581 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.2508/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153674638 CMS
ABBVIE INC. $29.7408/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106342081 CMS
Phathom Pharmaceuticals, Inc. $102.0008/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151139579 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.8607/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153518358 CMS
Regeneron Healthcare Solutions, Inc. $22.2507/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114255671 CMS
ABBVIE INC. $19.6707/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106342079 CMS
Phathom Pharmaceuticals, Inc. $29.3007/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151139569 CMS
Phathom Pharmaceuticals, Inc. $29.3007/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151139571 CMS
Phathom Pharmaceuticals, Inc. $55.6107/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151139573 CMS
Phathom Pharmaceuticals, Inc. $47.8707/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151139575 CMS
Phathom Pharmaceuticals, Inc. $35.2307/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151139577 CMS
Phathom Pharmaceuticals, Inc. $511.4407/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151139563 CMS
Phathom Pharmaceuticals, Inc. $135.0007/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151139565 CMS
Phathom Pharmaceuticals, Inc. $346.0907/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151139567 CMS
Phathom Pharmaceuticals, Inc. $3,010.0007/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151139561 CMS
Organon Llc $15.9907/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136297587 CMS
Janssen Biotech, Inc. $18.7207/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078783608 CMS
Celgene Corporation $20.2207/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101110066 CMS
ABBVIE INC. $17.8507/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106342077 CMS
Alkermes, Inc. $27.3307/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120620802 CMS
Intercept Pharmaceuticals, Inc. $17.6807/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113639437 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.6307/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153605506 CMS
ABBVIE INC. $1.8007/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106342075 CMS
AIMMUNE THERAPEUTICS, INC. $18.6607/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146987863 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.2407/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137698032 CMS
ABBVIE INC. $30.5306/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106342073 CMS
Phathom Pharmaceuticals, Inc. $1,720.0006/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151139559 CMS
PFIZER INC. $18.6506/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131693771 CMS
Phathom Pharmaceuticals, Inc. $126.5206/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151139557 CMS
Celltrion USA Inc. $14.0006/17/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1075859865 CMS
ABBVIE INC. $19.3906/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106342071 CMS
Janssen Biotech, Inc. $15.3806/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078783551 CMS
Phathom Pharmaceuticals, Inc. $43.5506/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151139555 CMS
Phathom Pharmaceuticals, Inc. $13.8706/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151139553 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $564.10 37
PY2020 $353.25 15
PY2021 $1,444.51 77
PY2022 $2,515.50 150
PY2023 $2,837.37 161
PY2024 $40,123.85 189
PY2025 $4,567.35 138

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $366,525.50 155
PY2024 Principal investigator $84,505.78 16

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

155 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $2,459.16 12/22/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772085
Principal investigator 1 Boehringer Ingelheim International GmbH $4,077.48 12/19/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760079
Principal investigator 1 Boehringer Ingelheim International GmbH $543.18 12/19/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760081
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 12/17/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772107
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 12/17/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772109
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $2,793.00 12/17/2025 Non-covered Recipient Entity
GI ASSOCIATES RESEARCH LLC
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211610864
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $12,161.00 12/17/2025 Non-covered Recipient Entity
GI ASSOCIATES RESEARCH LLC
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211610868
Principal investigator 1 ABBVIE INC. $3,512.52 12/04/2025 Non-covered Recipient Entity
GI ASSOCIATES RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202528752
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 12/03/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772087
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 12/03/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772089
Principal investigator 1 Boehringer Ingelheim International GmbH $389.40 11/28/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760045
Principal investigator 1 Boehringer Ingelheim International GmbH $75.00 11/28/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760073
Principal investigator 1 Boehringer Ingelheim International GmbH $543.18 11/27/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760047
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 11/27/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760049
Principal investigator 1 Boehringer Ingelheim International GmbH $2,814.24 11/27/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760051
Principal investigator 1 Boehringer Ingelheim International GmbH $543.18 11/27/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760059
Principal investigator 1 Boehringer Ingelheim International GmbH $3,916.44 11/27/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760063
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 11/27/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760065
Principal investigator 1 Boehringer Ingelheim International GmbH $1,981.32 11/27/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760067
Principal investigator 1 Boehringer Ingelheim International GmbH $3,905.88 11/27/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760077
Principal investigator 1 Boehringer Ingelheim International GmbH $1,557.60 11/27/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772081
Principal investigator 1 Boehringer Ingelheim International GmbH $1,557.60 11/27/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772083
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 11/19/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760085
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 11/19/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760087
Principal investigator 1 Boehringer Ingelheim International GmbH $126.10 11/19/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760089
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 11/19/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760091
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 11/19/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772095
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 11/19/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772097
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 11/19/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772099
Principal investigator 1 Boehringer Ingelheim International GmbH $126.10 11/19/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772101
Principal investigator 1 Boehringer Ingelheim International GmbH $29.31 11/19/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772103
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 11/19/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772105
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 11/17/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760041
Principal investigator 1 Boehringer Ingelheim International GmbH $594.00 11/17/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760043
Principal investigator 1 Boehringer Ingelheim International GmbH $4,884.00 11/17/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760053
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 11/17/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760055
Principal investigator 1 Boehringer Ingelheim International GmbH $3,905.88 11/17/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760057
Principal investigator 1 Boehringer Ingelheim International GmbH $1,561.32 11/17/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760061
Principal investigator 1 Boehringer Ingelheim International GmbH $14,729.68 11/17/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760069
Principal investigator 1 Boehringer Ingelheim International GmbH $75.00 11/17/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760071
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 11/17/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760075
Principal investigator 1 ABBVIE INC. $27,397.26 11/05/2025 Non-covered Recipient Entity
GI ASSOCIATES RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202522949
Principal investigator 1 Boehringer Ingelheim International GmbH $1,200.00 10/29/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772047
Principal investigator 1 Boehringer Ingelheim International GmbH $3,839.88 10/29/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772061
Principal investigator 1 Boehringer Ingelheim International GmbH $3,839.88 10/29/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772063
Principal investigator 1 Boehringer Ingelheim International GmbH $4,898.52 10/29/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772067
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 10/27/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760083
Principal investigator 1 Boehringer Ingelheim International GmbH $2,345.64 10/27/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772053
Principal investigator 1 Boehringer Ingelheim International GmbH $1,557.60 10/27/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772065
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 10/27/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772091
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 10/27/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772093
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 10/24/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772049
Principal investigator 1 Boehringer Ingelheim International GmbH $624.36 10/24/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772051
Principal investigator 1 Boehringer Ingelheim International GmbH $8,351.00 10/24/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772055
Principal investigator 1 Boehringer Ingelheim International GmbH $7,260.00 10/24/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772057
Principal investigator 1 Boehringer Ingelheim International GmbH $266.64 10/24/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772059
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 10/22/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772069
Principal investigator 1 Boehringer Ingelheim International GmbH $4,884.00 10/22/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772071
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 10/22/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772073
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 10/22/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772075
Principal investigator 1 Boehringer Ingelheim International GmbH $4,884.00 10/22/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772077
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 10/22/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772079
Principal investigator 1 Boehringer Ingelheim International GmbH $307.56 10/15/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760025
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 10/15/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760027
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 10/15/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760029
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 10/15/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760031
Principal investigator 1 Boehringer Ingelheim International GmbH $75.00 10/15/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760033
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 10/15/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760035
Principal investigator 1 Boehringer Ingelheim International GmbH $1,320.00 10/15/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760037
Principal investigator 1 Boehringer Ingelheim International GmbH $4,884.00 10/15/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760039
Principal investigator 1 ABBVIE INC. $8,473.08 10/09/2025 Non-covered Recipient Entity
GI ASSOCIATES RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202516367
Principal investigator 1 Boehringer Ingelheim International GmbH $1,200.00 10/08/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760023
Principal investigator 1 Boehringer Ingelheim International GmbH $3,916.44 09/29/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760021
Principal investigator 1 Boehringer Ingelheim International GmbH $1,887.60 09/26/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772033
Principal investigator 1 Boehringer Ingelheim International GmbH $760.98 09/26/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772035
Principal investigator 1 Boehringer Ingelheim International GmbH $2,345.64 09/26/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772037
Principal investigator 1 Boehringer Ingelheim International GmbH $760.98 09/26/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772039
Principal investigator 1 Boehringer Ingelheim International GmbH $2,571.36 09/26/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772041
Principal investigator 1 Boehringer Ingelheim International GmbH $1,557.60 09/26/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772043
Principal investigator 1 Boehringer Ingelheim International GmbH $1,557.60 09/26/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772045
Principal investigator 1 Boehringer Ingelheim International GmbH $11.66 09/24/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760011
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 09/24/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760013
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 09/24/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760015
Principal investigator 1 Boehringer Ingelheim International GmbH $126.10 09/24/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760017
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 09/24/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760019
Principal investigator 1 Boehringer Ingelheim International GmbH $11.66 09/24/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772025
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 09/24/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772027
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 09/24/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772029
Principal investigator 1 Boehringer Ingelheim International GmbH $126.10 09/24/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772031
Principal investigator 1 ABBVIE INC. $8,473.08 09/10/2025 Non-covered Recipient Entity
GI ASSOCIATES RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202510434
Principal investigator 1 Boehringer Ingelheim International GmbH $760.98 08/28/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772005
Principal investigator 1 Boehringer Ingelheim International GmbH $760.98 08/28/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772011
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 08/26/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760007
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 08/26/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760009
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 08/26/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772019
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 08/26/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772021
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 08/26/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772023
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 08/13/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771995
Principal investigator 1 Boehringer Ingelheim International GmbH $624.36 08/13/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771997
Principal investigator 1 Boehringer Ingelheim International GmbH $4,884.00 08/13/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771999
Principal investigator 1 Boehringer Ingelheim International GmbH $4,884.00 08/13/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772001
Principal investigator 1 Boehringer Ingelheim International GmbH $7,260.00 08/13/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772003
Principal investigator 1 Boehringer Ingelheim International GmbH $307.56 08/13/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772007
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 08/13/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772009
Principal investigator 1 Boehringer Ingelheim International GmbH $266.64 08/13/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772013
Principal investigator 1 ABBVIE INC. $8,473.08 08/07/2025 Non-covered Recipient Entity
GI ASSOCIATES RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202503945
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 08/01/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760001
Principal investigator 1 Boehringer Ingelheim International GmbH $253.20 08/01/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760003
Principal investigator 1 Boehringer Ingelheim International GmbH $21.43 07/31/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771987
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 07/31/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771989
Principal investigator 1 Boehringer Ingelheim International GmbH $62.00 07/31/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771991
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 07/31/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771993
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 07/28/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760005
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 07/28/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772015
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 07/28/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220772017
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 07/10/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220759999
Principal investigator 1 ABBVIE INC. $16,591.08 07/08/2025 Non-covered Recipient Entity
GI ASSOCIATES RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202497030
Principal investigator 1 ABBVIE INC. $8,473.08 07/08/2025 Non-covered Recipient Entity
GI ASSOCIATES RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202497046
Principal investigator 1 ABBVIE INC. $5,169.56 07/02/2025 Non-covered Recipient Entity
GI ASSOCIATES RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202494229
Principal investigator 1 Boehringer Ingelheim International GmbH $4,882.68 06/30/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771949
Principal investigator 1 Boehringer Ingelheim International GmbH $4,898.52 06/30/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771961
Principal investigator 1 Boehringer Ingelheim International GmbH $3,895.32 06/30/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771963
Principal investigator 1 Boehringer Ingelheim International GmbH $3,879.48 06/30/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771965
Principal investigator 1 Boehringer Ingelheim International GmbH $389.40 06/27/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771951
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 06/27/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771953
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 06/27/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771957
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 06/24/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771947
Principal investigator 1 Boehringer Ingelheim International GmbH $266.64 06/24/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771955
Principal investigator 1 Boehringer Ingelheim International GmbH $624.36 06/24/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771959
Principal investigator 1 Boehringer Ingelheim International GmbH $7,260.00 06/24/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771967
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 06/24/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771983
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 06/24/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771985
Principal investigator 1 ABBVIE INC. $8,473.08 06/05/2025 Non-covered Recipient Entity
GI ASSOCIATES RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202490387
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 05/29/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771969
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 05/27/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771977
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 05/27/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771979
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 05/27/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771981
Principal investigator 1 Caris MPI, Inc. $5,000.00 05/09/2025 Non-covered Recipient Entity
GI ASSOCIATES RESEARCH LLC
THE CARIS BIOREPOSITORY RESEARCH PROTOCOL No dispute reported 06/30/2026 1234284888
Principal investigator 1 ABBVIE INC. $97.68 05/08/2025 Non-covered Recipient Entity
GI ASSOCIATES RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202484501
Principal investigator 1 ABBVIE INC. $13,620.64 05/07/2025 Non-covered Recipient Entity
GI ASSOCIATES RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202484017
Principal investigator 1 ABBVIE INC. $3,218.00 05/07/2025 Non-covered Recipient Entity
GI ASSOCIATES RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202484019
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 04/23/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220759991
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 04/23/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220759993
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 04/23/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220759995
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 04/23/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220759997
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 04/23/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771971
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 04/23/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771973
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 04/23/2025 Non-covered Recipient Entity
Gastrointestinal Associates LLP
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220771975
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 04/17/2025 Non-covered Recipient Entity
GI Associates Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220759989
Principal investigator 1 ABBVIE INC. $8,473.08 04/09/2025 Non-covered Recipient Entity
GI ASSOCIATES RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202475210
Principal investigator 1 ABBVIE INC. $9,643.04 04/03/2025 Non-covered Recipient Entity
GI ASSOCIATES RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202473348
Principal investigator 1 ABBVIE INC. $8,631.48 03/13/2025 Non-covered Recipient Entity
GI ASSOCIATES RESEARCH LLC
M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202463096
Principal investigator 1 ABBVIE INC. $5,927.90 03/07/2025 Non-covered Recipient Entity
GI ASSOCIATES RESEARCH LLC
M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202459576
Principal investigator 1 ABBVIE INC. $3,218.00 02/27/2025 Non-covered Recipient Entity
GI ASSOCIATES RESEARCH LLC
M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202454261
Principal investigator 1 ABBVIE INC. $15,076.00 01/28/2025 Non-covered Recipient Entity
GI ASSOCIATES RESEARCH LLC
M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202441507